Merck releases new data on Keytruda® (pembrolizumab) in resected stage II melanoma

Sep 18, 2021

Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically meaningful improvement in recurrence-free survival compared to placebo in patients with resected high-risk stage II melanoma.

Print Page Mail Article